Format

Send to

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):593-604. doi: 10.1016/j.beem.2011.05.001.

The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃.

Author information

1
Laboratory for Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Herestraat 49, Leuven, Belgium. Els.Vanoirbeek@med.kuleuven.be

Abstract

Various epidemiological studies have shown an aetiological link between vitamin D deficiency and cancer incidence. The active metabolite of vitamin D, 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃], has potent anti-cancer activities both in vitro and in vivo. These anti-cancer effects are attained by regulating the transcription of numerous genes that are involved in different pathways to reduce tumorigenesis and are dependent on the cancer cell type. Besides reducing cell growth and inducing apoptosis, 1,25(OH)₂D₃ also inhibits angiogenesis and metastasis. Moreover, its potency to inhibit inflammation also contributes to its anti-tumoral activity. Here, we report the different ways in which 1,25(OH)₂D₃ interferes with the malignant processes that are activated in cancer cells.

PMID:
21872801
PMCID:
PMC3164534
DOI:
10.1016/j.beem.2011.05.001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center